The poster builds an indirect-benefit thesis for photonic interconnect company POET Technologies around a chain of “Lumilens financing—commercial orders—equity warrants—potential Intel collaboration.” A LinkedIn screenshot in the attachment shows Lumilens founder Ankur Singla thanking Intel CEO Lip-Bu Tan for supporting the company since its early days; Tan describes himself as an early investor and congratulates Lumilens on completing a $700 million financing. The title of the link attached to the screenshot says the company has raised more than $900 million in total, so the $700 million is more likely the size of the current round rather than cumulative funding. Based on this, the poster argues that Tan's private investment in Lumilens can be viewed as indirect exposure to POET: Lumilens has placed an initial $50 million order with POET for EOI optical engines, and if the parties' framework meets development, qualification, and payment conditions, cumulative purchases over five years could exceed $500 million. POET also granted Lumilens warrants for up to approximately 22.92 million shares at an exercise price of $8.25 with a nine-year term. Only approximately 2.29 million shares are immediately exercisable, while the remainder vest in tranches as Lumilens makes cumulative payments on subsequent orders. Therefore, increased Lumilens shipments could indeed raise both POET's revenue and the value of the warrants held by Lumilens, but this does not mean Tan directly owns POET securities, nor does it prove that Intel is involved in a collaboration. The poster further speculates that Lumilens' disclosed first customer is one of the world's top two hyperscalers and that Tan's investment may foreshadow a future agreement between Intel and Lumilens, potentially bringing POET into a larger AI data center supply chain. This inference currently lacks support from contracts, customer identification, or official Intel disclosures. The poster also cites a 184% increase in Citadel's position, a new 1.1 million-share position by Group One, and holdings by prominent community accounts to suggest rising institutional interest, but provides no filing dates, ownership percentages, or indication of whether these are market-making or hedging positions. On valuation, the poster interprets MMCAP's participation in an approximately $400 million financing in May 2026 at a combined price of $21 per share and accompanying warrant, with a warrant exercise price of $26.25, as meaning that a potential acquisition price would not be below $26.25, and therefore believes the risk of high-strike LEAPS has decreased. This purported “acquisition floor” is invalid: $21 is the combined price of the shares and warrants, while $26.25 is only the warrant exercise price. Public filings do not grant MMCAP an explicit right to block an acquisition at that price, and MMCAP could also manage its risk through hedging, transfers, or accepting transaction consideration. The poster's position consists of 130 POET call option contracts expiring in January 2028 with a $17 strike price, which is in practice a highly leveraged, long-duration bet rather than conservative exposure. Manufacturing expansion and mass-production progress reported in the latest earnings release are direct catalysts. The biggest flaw is the sequential extrapolation from a private investment, a potential purchase ceiling, and a warrant arrangement into Intel's commercial endorsement, while underestimating customer qualification, order conversion, capacity-expansion execution, warrant and financing dilution, and option time-value decay.